Abstract
CBDCA is a second generation platinum coordination complex that is presently in clinical trial. The principal advantage of this agent over cis-diamminedichloroplatinum (II) (cisplatin) is a reduction in its nephrotoxicity and acute gastrointestinal toxicity. These features of the drug were initially described in preclinical toxicologic studies and have now been confirmed in several Phase I clinical trials (1–4). Clinical pharmacologic studies have been performed as a part of several of these trials and this paper summarizes the results obtained at Georgetown as well as two other centers and draws comparison, where possible, to data for cisplatin.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Calvert, AH, Harland, SJ, Newell, DR, Siddik, H, Jones, AC, McElwain, TJ, Raju, S, Wiltshaw, E, Smith, IE, Baker, JM, Peckham, MJ, and Harrap, KR (1982): Early Clinical Studies with Cis-Diammine-1,1-cyclobutane Dicarboxylate Platinum II. Cancer Chemother. Pharmacol. 9:140–147.
Curt, GA, Grygiel, JJ, Weiss, R, Corden, B, Ozols, R, Tell, D, Collins, J and Myers, CE (1983): A Phase I and Pharmacokinetic Study of CBDCA (NSC 241240) Proc. Amer. Soc. Clin. Onc. 2:21.
Egorin, MJ, Van Echo, DA, Witacre, MY, Olman, EA and Aisner, J (1983): Phase I Study and Clinical Pharmacokinetics of Carboplatin (CBDCA). Proc. Amer. Soc. Clin. Onc. 2:28.
Priego, V, Luc, V, Bonnern, E, Rahman, A, Smith, F, Schein, P, and Woolley, P (1983): A Phase I Study and Pharmacology of Diarmrine-(1,1)-cyclobutane dicarboxylato (2-)-0,0′-platinum (CBDCA) Administered on a Weekly Schedule. Proc. Amer. Soc. Clin. Onc. 2:30.
Gullo, J, Litterst, C, Maguire, P, Sikic, BI, Hoth, DF, and Woolley, P (1980): Pharmacokinetics and Protein Binding of Cis-Dichlorodiamninoplatinum (II) Administered as a One Hour or as a Twenty Hour Infusion. Cancer Chemother. Pharmacol. 5:21–26.
Gormley, P, Bull, JM, LeRoy, AF and Cysyk, R (1979): Kinetics of cis-Dichlorodiamminoplatium. Clin. Pharmacol. Ther. 25: 351–358.
Patton, TF, Himmelstein, KJ, Belt, R, Bannister, SJ, Sternson, LA and Repta, AJ (1978): Plasma Levels and Urinary Excretion of Filterable Platinum Species Following Bolus Injection and IV Infusion of cis-Dichlorodiamminoplatinum (II) in Man. Cancer Treat. Rep. 62:1359–1365.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Woolley, P.V., Priego, V.M., Luc, P.V.T., Rahman, A., Schein, P.S. (1984). Clinical Pharmacokinetics of Diammine [1,1-Cydobutanedicarboxylato (2-)]-0,0′-Platinum (CBDCA). In: Hacker, M.P., Douple, E.B., Krakoff, I.H. (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Developments in Oncology, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2837-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2837-7_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-89838-619-6
Online ISBN: 978-1-4613-2837-7
eBook Packages: Springer Book Archive